Launch of a pilot project in the Life Wellness field by a consolidated subsidiary and the associated expenses
CrypTech Capital (the Company's consolidated subsidiary)
The spectacle-shaped device that Scala,Inc. plans to file as a general medical device (the Product)
To diversify the earnings base and create new growth opportunities, and to determine whether to launch a sales business for the Product after confirming expert opinions, the scope of target users, the manufacturing method, profitability and other factors.
The Company plans to incur expenses of up to ¥9.5 million in total, excluding tax. The expenses are expected to be recognized in the fiscal year ending May 2027, reducing ordinary profit and net income attributable to owners of the parent by the same amount.
Fiscal year ending May 2027
The expenses described above are expected to be incurred and affect consolidated results for the fiscal year ending May 2027. The Company will promptly announce any significant changes in the future.
The pilot project will be conducted from November 2026 to March 2027, and the Company will decide by March 2027 whether to launch the sales business. If it decides to proceed, it will finalize the terms of the final agreement and resubmit the launch of the sales business and execution of the final agreement to the Company's Board of Directors for approval.
The Company will promptly announce any changes to the plan or schedule for the pilot project, any decision to launch or not to launch the sales business, or any other matter requiring disclosure.
| Item | Details |
|---|---|
| Event name | Launch of a pilot project in the Life Wellness field by a consolidated subsidiary and the associated expenses |
| Date of occurrence | 9 November 2026 (date of resolution by the Company's Board of Directors) |
| Subject Entity | CrypTech Capital (the Company's consolidated subsidiary) |
| Target Locations / Products | The spectacle-shaped device that Scala,Inc. plans to file as a general medical device (the Product) |
| Cause | To diversify the earnings base and create new growth opportunities, and to determine whether to launch a sales business for the Product after confirming expert opinions, the scope of target users, the manufacturing method, profitability and other factors. |
| Amount of Impact on Business Performance | The Company plans to incur expenses of up to ¥9.5 million in total, excluding tax. The expenses are expected to be recognized in the fiscal year ending May 2027, reducing ordinary profit and net income attributable to owners of the parent by the same amount. |
| Accounting period in which recognized | Fiscal year ending May 2027 |
| Impact on Earnings Forecast | The expenses described above are expected to be incurred and affect consolidated results for the fiscal year ending May 2027. The Company will promptly announce any significant changes in the future. |
| Outlook | The pilot project will be conducted from November 2026 to March 2027, and the Company will decide by March 2027 whether to launch the sales business. If it decides to proceed, it will finalize the terms of the final agreement and resubmit the launch of the sales business and execution of the final agreement to the Company's Board of Directors for approval. |
| Planned follow-up disclosure | The Company will promptly announce any changes to the plan or schedule for the pilot project, any decision to launch or not to launch the sales business, or any other matter requiring disclosure. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To diversify the earnings base and create new growth opportunities, while carefully determining whether to launch the sales business after confirming expert opinions, the target users, the manufacturing method and profitability.